Nutex Health Restates 2024 Financials, Cites Material Weakness

Ticker: NUTX · Form: 10-K/A · Filed: Nov 18, 2025 · CIK: 1479681

Sentiment: bearish

Topics: Restatement, Material Weakness, Internal Controls, Healthcare Services, SEC Filing, Accounting Errors, Financial Reporting

TL;DR

**NUTX's restatement and new material weakness are red flags for investors, signaling deeper accounting issues despite the 'immaterial' financial impact.**

AI Summary

Nutex Health Inc. (NUTX) filed an Amendment No. 2 to its 2024 Form 10-K, restating previously issued consolidated financial statements primarily to reclassify $16.4 million in non-cash stock-based compensation obligations from equity to liabilities. This reclassification, along with other immaterial adjustments, resulted in a $13.4 million (2.9%) increase in total liabilities and a corresponding $13.4 million (6.6%) decrease in total equity as of December 31, 2024. Net income for the year decreased by approximately $0.5 million (0.5%), leading to a $0.02 decrease in both diluted and basic earnings per share, to $9.69 and $10.23 respectively. The company also disclosed an additional material weakness in internal control over financial reporting related to complex accounting matters. Despite these adjustments, key metrics such as revenue, liquidity, debt, operating cash flow, adjusted EBITDA, and patient visits were not materially affected. Nutex Health operates 24 hospital facilities in 11 states and a population health management division, employing 800 full-time staff and contracting 255 doctors.

Why It Matters

This restatement signals potential accounting complexities and control deficiencies at Nutex Health, which could erode investor confidence despite the 'immaterial' impact on net income. The reclassification of $16.4 million from equity to liabilities alters the balance sheet structure, potentially affecting debt covenants or perceived financial stability. For employees and customers, the operational impact is minimal, as revenue and patient visits remain unaffected. However, the disclosed material weakness in internal controls suggests a need for robust oversight, which could impact the company's competitive standing against more financially transparent healthcare providers.

Risk Assessment

Risk Level: high — The filing explicitly states an 'additional material weakness in the design and operating effectiveness of internal control over financial reporting as of December 31, 2024 related to timely and accurately analyzing and accounting for complex and non-routine accounting matters.' This, coupled with the restatement of $16.4 million in obligations from equity to liabilities and a $13.4 million decrease in total equity, indicates significant control deficiencies and potential for future accounting errors.

Analyst Insight

Investors should exercise extreme caution and thoroughly scrutinize Nutex Health's future filings for evidence of remediation of the material weaknesses. Consider delaying any investment decisions until the company demonstrates a strengthened internal control environment and consistent, accurate financial reporting. Existing investors should re-evaluate their position given the increased financial reporting risk.

Financial Highlights

debt To Equity
Not Disclosed
revenue
Not Disclosed
operating Margin
Not Disclosed
total Assets
Not Disclosed
total Debt
Not Disclosed
net Income
Not Disclosed
eps
$9.69
gross Margin
Not Disclosed
cash Position
Not Disclosed
revenue Growth
Not Disclosed

Revenue Breakdown

SegmentRevenueGrowth
Hospital DivisionNot DisclosedNot Disclosed
PHM DivisionNot DisclosedNot Disclosed
Real Estate DivisionNot DisclosedNot Disclosed

Key Numbers

Key Players & Entities

FAQ

Why did Nutex Health Inc. restate its 2024 financial statements?

Nutex Health Inc. restated its 2024 financial statements primarily to reclassify $16.4 million in non-cash stock-based compensation obligations related to under-construction and ramping hospitals from equity to liabilities, in accordance with ASC 718 and ASC 480. Additionally, immaterial adjustments were made, including reclassifying $3.5 million in related-party accounts payable to equity.

What was the impact of the restatement on Nutex Health's financial position?

As a result of the restatement, Nutex Health's total liabilities as of December 31, 2024, increased by $13.4 million (2.9%), and total equity correspondingly decreased by $13.4 million (6.6%). Net income for the year decreased by approximately $0.5 million (0.5%).

Did the restatement affect Nutex Health's revenue or cash flow?

No, the adjustments made in the restatement were non-cash in nature and had no material effect on key metrics including revenue, liquidity, short-term and long-term debt, operating cash flow, adjusted EBITDA, or the number of patient visits for the periods presented.

What is the significance of the additional material weakness disclosed by Nutex Health?

The additional material weakness in internal control over financial reporting, related to timely and accurately analyzing and accounting for complex and non-routine accounting matters, is significant because it indicates a deficiency in the company's ability to ensure reliable financial reporting. This could lead to further errors or restatements if not effectively remediated.

What steps is Nutex Health taking to address its internal control weaknesses?

Nutex Health has engaged an accounting firm to assist in the proper design, implementation, and testing of internal controls over financial reporting. Training for relevant personnel is ongoing, and management is undertaking additional efforts to remediate the identified material weaknesses and strengthen the overall control environment.

Who audited Nutex Health's restated financial statements?

The previously issued financial statements for the year ended December 31, 2024, were audited by Marcum LLP. Following the Audit Committee's decision to restate, Nutex Health engaged Grant Thornton LLP as its independent registered public accounting firm to re-audit the consolidated financial statements for the year ended December 31, 2024.

What is Nutex Health's Compensation Recovery Policy and was it triggered by the restatement?

Nutex Health established a Compensation Recovery Policy effective October 2, 2023, for recoupment of certain performance-based compensation. The Compensation Committee determined that no performance-based compensation within the prior three years was primarily based on the financial results that required restatement, so no recovery obligation was triggered.

What are Nutex Health's primary business segments?

Nutex Health operates through three primary segments: the hospital division, which develops and operates 24 micro-hospitals, specialty hospitals, and hospital outpatient departments; the population health management (PHM) division, which owns and operates provider networks; and the real estate division.

How many employees and doctors does Nutex Health have?

Nutex Health employs 800 full-time employees and contracts 255 doctors at its facilities. Additionally, it partners with over 2,100 physicians and specialists within its population health management networks.

What were the reverse stock splits for Nutex Health in 2024?

Nutex Health effected a 1-15 reverse stock split on April 9, 2024, and an additional 1-10 reverse stock split on July 2, 2024. All authorized, issued, and outstanding stock and per share amounts in the Annual Report on Form 10-K/A have been adjusted to reflect these 2024 Reverse Stock Splits.

Risk Factors

Industry Context

Nutex Health operates in the highly competitive healthcare services sector, focusing on both hospital operations and population health management. The industry is characterized by evolving reimbursement models, increasing regulatory scrutiny, and a growing emphasis on value-based care. Companies like Nutex Health are navigating these trends by operating specialized facilities like micro-hospitals and developing integrated care networks.

Regulatory Implications

The company's out-of-network provider status presents potential regulatory and reimbursement risks. Changes in healthcare policy, particularly concerning out-of-network billing and surprise medical bills, could significantly impact revenue streams. Furthermore, the disclosure of a material weakness in internal controls necessitates close monitoring by regulatory bodies and could lead to increased compliance burdens.

What Investors Should Do

  1. Monitor future filings for remediation of material weakness.
  2. Analyze the impact of out-of-network status on revenue stability.
  3. Evaluate the financial performance and development of new facilities.

Key Dates

Glossary

Form 10-K/A
An amended annual report filed with the SEC to correct or supplement information in a previously filed annual report. (This filing is an amendment to Nutex Health's 2024 Form 10-K, indicating corrections to its financial reporting.)
Non-cash stock-based compensation obligations
Compensation awarded in the form of stock or stock options that does not involve an immediate outflow of cash from the company. (The reclassification of $16.4 million of these obligations from equity to liabilities significantly impacted the company's balance sheet.)
Material Weakness
A deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (The disclosure of a material weakness raises concerns about the reliability of the company's financial reporting processes.)
Micro-hospitals
Small, community-based hospitals that provide a limited range of services, often focusing on emergency care and short-stay inpatient services. (These are a key component of Nutex Health's hospital division, contributing to its operational strategy.)
Population Health Management (PHM)
A strategy and approach to healthcare that aims to improve the health outcomes of a defined patient population while reducing the per capita cost of care. (This is a significant division for Nutex Health, focusing on managing patient populations and provider networks.)
Independent Physician Association (IPA)
A type of physician organization that contracts with managed care plans and other entities to provide medical services to patients. (IPAs are part of Nutex Health's PHM division, indicating a network-based approach to care delivery.)
Out-of-network provider
A healthcare provider that does not have a contract with a patient's health insurance plan. (This operational model for the hospital division impacts revenue and reimbursement strategies.)

Year-Over-Year Comparison

This amended filing (10-K/A) primarily addresses a restatement of previously issued financial statements for the year ended December 31, 2024. The key change is the reclassification of $16.4 million in non-cash stock-based compensation obligations from equity to liabilities, increasing total liabilities by $13.4 million and decreasing total equity by $13.4 million. Net income saw a minor decrease of $0.5 million, impacting EPS by $0.02. A new material weakness in internal controls was also disclosed, which was not present in the original filing.

Filing Stats: 4,419 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2025-11-18 16:23:02

Key Financial Figures

Filing Documents

- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Part II - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

- Item 8. Financial Statements and Supplementary Data

Part II - Item 8. Financial Statements and Supplementary Data.

- Item 9A. Controls and Procedures

Part II - Item 9A. Controls and Procedures.

- Item 14. Principal Accountant Fees and Service

Part III - Item 14. Principal Accountant Fees and Service

- Item 15. Exhibits and Financial Statement Schedules

Part IV - Item 15. Exhibits and Financial Statement Schedules. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the certifications specified in Rule 13a-14 under the Exchange Act from the Company's Chief Executive Officer and its Chief Financial Officer, dated as of the date hereof, are being filed or furnished, as applicable, with this Form 10-K/A as Exhibits 31.1, 31.2, 32.1 and 32.2, and updated and additional Consents of Independent Registered Public Accounting Firm are being filed as Exhibit 23.1 and 23.2. This Form 10-K/A also includes updated and additional, as applicable, Reports of Independent Registered Public Accounting Firm and updated signature page. Except as otherwise provided, the disclosures in this Form 10-K/A are made as of the date of the Original Form 10-K and do not reflect any events that occurred after the date of the Original Form 10-K or modify or update any other disclosures in the Original Form 10-K affected by subsequent events. As such, forward-looking statements included in this Form 10-K/A may represent management's views as of the date of the Original Form 10-K and should not be assumed to be accurate as of any date thereafter. Restatement Background As previously disclosed in the Company's Current Report Form 8-K filed on August 21, 2025 , the Audit Committee of the Board of Directors of Nutex Health (the "Audit Committee"), after consultation with the Chief Financial Officer, concluded that the Company's previously issued consolidated financial statements as of and for the year ended December 31, 2024 contained in the Original Form 10-K (the "Previously Issued Financial Statements") should be restated to reclassify non-cash stock-based compensation obligations related to under-construction and ramping hospitals as liabilities rather than equity. Further, the Company is also recording certain immaterial adjustments as described below. Please read Note 1 of the Consolidate

Risk Factors

Risk Factors 12 Item 1B. Unresolved Staff Comments 33 Item 1C. Cybersecurity 33 Item 2.

Properties

Properties 34 Item 3.

Legal Proceedings

Legal Proceedings 34 Item 4. Mine Safety Disclosures 35 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 36 Item 6. Reserved 36 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 50 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 50 Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 96 Item 9A.

Controls and Procedures

Controls and Procedures 96 Item 9B. Other Information 98 Item 9C . Disclosures Regarding Foreign Jurisdiction that Prevent Inspections 98 PART III Item 10. Directors, Executive Officers and Corporate Governance 98 Item 11.

Executive Compensation

Executive Compensation 98 Item 12.

Security Ownership of Certain Beneficial Owners and Management And Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management And Related Stockholder Matters 98 Item 13. Certain Relationships and Related Transactions and Director Independence 98 Item 14. Principal Accountant Fees and Services 98 Item 15. Exhibits and Financial Statement Schedules 101

Signatures

Signatures 105 Table of Contents PART I

Business

Item 1. Business Overview Nutex Health Inc. ("Nutex Health" or the "Company") is a physician-led, healthcare services and operations company with 24 hospital facilities in 11 states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments ("HOPDs"). The population health management ("PHM") division owns and operates provider networks such as independent physician associations ("IPAs"). We employ 800 full-time employees, contract 255 doctors at our facilities and partner with over 2,100 physicians and specialists within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware. Operating Segments We report the results of our operations as three segments: (i) the hospital division, (ii) the PHM division, and (iii) the real estate division. Hospital Division. Our hospital division develops and operates a network of micro-hospitals, specialty hospitals and HOPDs providing comprehensive and high-quality 24/7 care. Our full-service care delivery model provides concierge-level care traditionally offered by larger hospitals in a patient-friendly and cost-effective setting. We provide a full spectrum of healthcare services, including emergency room care, inpatient care, and behavioral health, and offer a complementary suite of ancillary services, including onsite imaging (CT scan, X-ray, MRI, ultrasound, etc.), certified and accredited laboratories, and onsite inpatient pharmacies. We own and operate 24 healthcare facilities across 11 states and currently have an additional 10 de novo micro-hospitals under various stages of development. Our micro-hospitals generate revenue from both emergency services and in-patient services, providing operating leverage and significant earning potential of eac

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing